Study guide
3.3 Risk-Based Monitoring (RBM), Centralized Monitoring & Source Data Verification (SDV vs SDR)
ACRP Certified Professional ACRP-CP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: GCP Principles, Roles & Delegation
1.1 The Eleven ICH E6(R3) Principles of GCP & Guideline Structure 1.2 Sponsor & Investigator Responsibilities and Delegation of Authority 1.3 Staff Training, Qualifications & Delegation of Authority Log (DOAL) 1.4 CRO Oversight, Vendor Management & Transfer of Regulatory Obligations (TORO)
2 Chapter 2: Essential Records, Source Documentation & Data Confidentiality
2.1 Essential Records Before, During and After the Trial (ICH E6(R3) Appendix C) 2.2 Trial Master File (TMF) and Investigator Site File (ISF) Structure & Inspection Readiness 2.3 Source Documentation, ALCOAC Principles & Medical Record Standards 2.4 Confidentiality, Privacy & Protection of Participant Personal Information
3 Chapter 3: Monitoring, Quality Management & Audits
3.1 Risk-Based Quality Management (RBQM) & Quality Management Systems (QMS) 3.2 Monitoring Visit Types: Site Selection, SIV, IMV, and Close-Out 3.3 Risk-Based Monitoring (RBM), Centralized Monitoring & Source Data Verification (SDV vs SDR) 3.4 Quality Audits, Regulatory Inspections, Non-Compliance & Root Cause Analysis / CAPA
4 Chapter 4: Site Feasibility, Start-Up, Facilities & Laboratory Operations
4.1 Site Feasibility Assessment, Capability Analysis & Investigator Selection 4.2 Contractual Agreements: Clinical Trial Agreements, Budgets, Indemnification & Financial Arrangements 4.3 Site Initiation Preparation, System Access & Regulatory Greenlight 4.4 Protocol Review, Operational Feasibility & Institutional Approvals 4.5 Site Facilities, Equipment Maintenance, Calibration & Trial Supplies 4.6 Biological Samples & Hazardous Goods: Collection, Storage, Disposal & Shipment
5 Chapter 5: Subject Recruitment, Retention & Study Visits
5.1 Subject Recruitment Strategies, Advertising Guidelines & Ethical Constraints 5.2 Screening, Eligibility Verification & Inclusion/Exclusion Adherence 5.3 Subject Retention, Compliance, Visit Scheduling & Protocol Window Management 5.4 Managing Lost to Follow-Up, Subject Withdrawal & Early Termination Procedures
6 Chapter 6: Protocol Compliance, Deviations & Site Close-Out
6.1 Protocol Compliance, Waivers vs. Violations & Deviation Management 6.2 Investigational Site Close-Out Activities & Final Reconciliations 6.3 Record Retention, Archiving Requirements & Post-Trial Responsibilities
7 Chapter 7: Research Ethics, Vulnerable Populations & Research Integrity
7.1 Historical Milestones: Nuremberg Code, Belmont Report & Declaration of Helsinki 7.2 Ethical Principles: Beneficence, Non-Maleficence, Autonomy, Justice & Equipoise 7.3 Vulnerable Populations (Pediatrics, Pregnant Women, Prisoners, Cognitively Impaired, Economically Disadvantaged) 7.4 Conflict of Interest, Research Misconduct & Fraud in Clinical Research
8 Chapter 8: Informed Consent & Institutional Review Boards (IRB/IEC)
8.1 Informed Consent Elements, Process & Ongoing Consent / Re-Consent Requirements 8.2 Assent in Minors & Legally Acceptable Representative (LAR) Requirements 8.3 IRB/IEC Composition, Functions, Review Types (Full, Expedited, Exempt) & Continuing Review
9 Chapter 9: Safety Reporting & Adverse Event Management (ICH E2A)
9.1 Adverse Events (AE) vs. Adverse Drug Reactions (ADR) & Serious Adverse Events (SAE) Definitions 9.2 Causality Assessment, Expectedness, Reference Safety Information (RSI) & SUSARs 9.3 Expedited Reporting Timelines (7-day fatal/life-threatening, 15-day other serious) & Periodic Safety Updates (DSUR)
10 Chapter 10: Investigational Product (IP) Management & Accountability
10.1 Investigational Product Lifecycle, Labeling, Packaging & Blinding Procedures 10.2 IP Shipping, Receipt, Temperature Monitoring, Excursion Handling & Chain of Custody 10.3 IP Storage, Dispensing, Accountability Logs & Destruction/Return Procedures 10.4 Emergency Unblinding (Code Breaking) Protocols & Subject Safety Procedures
11 Chapter 11: Regulatory Frameworks, Submissions & Product Reference Information
11.1 Stakeholders, Regulatory Institutions & Global Frameworks in Clinical Research 11.2 Protocol Submission, Approval & Amendment Processes 11.3 Investigator's Brochure, Instructions for Use & Reference Product Information 11.4 Regulatory Reporting Requirements Before and After Marketing Authorisation
12 Chapter 12: Clinical Data Management, EDC & Electronic Records
12.1 Electronic Data Capture (EDC), eCRF Design & Clinical Data Management Systems (CDMS) 12.2 Computerised Systems, Data Governance & Audit Trails (ICH E6(R3) Annex 1 §4) 12.3 Data Validation, Edit Checks, Discrepancy / Query Management & Resolution 12.4 Medical Coding (MedDRA, WHO Drug), SAE Reconciliation, Data Transfer & Database Lock
13 Chapter 13: Trial Design, Biostatistics, Data Monitoring & Transparency
13.1 Phases of Clinical Research (Phase 0, I, II, III, IV) & Translational Medicine 13.2 Study Designs: Parallel, Crossover, Factorial, Adaptive & Non-Inferiority / Equivalence 13.3 Randomization Schemes, Stratification, Blinding Methods & Minimizing Bias 13.4 Endpoints (Primary, Secondary, Surrogate, Composite), Sample Size & Biostatistical Concepts (p-values, CI, ITT vs PP) 13.5 Interim Analyses, DSMB/IDMC Oversight & Efficacy and Safety Evaluation Milestones 13.6 Trial Registration, Results Transparency & Communicating Results to Participants
3.3 Risk-Based Monitoring (RBM), Centralized Monitoring & Source Data Verification (SDV vs SDR)
Key Takeaways Explain This Topic AI
Source Data Verification (SDV) is the mechanical comparison of transcribed eCRF data against original source records to confirm transcription accuracy.
Source Data Review (SDR) is the holistic, clinical evaluation of medical source documentation to assess protocol compliance, investigator oversight, medical decision-making, and unreported adverse events.
Centralized Statistical Monitoring (CSM) analyzes aggregate study data remotely across sites using statistical algorithms to identify data fabrication, digit preference, unusual variance, and systemic compliance outliers.
Modern Risk-Based Monitoring (RBM) integrates Centralized Monitoring, Remote Monitoring, and Targeted On-Site Monitoring into a coordinated oversight model.
Targeted SDV focuses resources on 100% verification of critical data (informed consent, primary efficacy endpoints, SAEs, IP dosing) while utilizing statistical sampling for secondary, low-risk data points.
Last updated: August 2026
Modern Multi-Modal Monitoring Architecture
Under ICH E6(R3) Annex 1 section 3.11.4 , sponsors are explicitly directed to develop monitoring strategies that combine on-site and centralized monitoring techniques tailored to the specific risks of the trial. Rather than relying on a single CRA traveling to every site on a fixed calendar schedule to perform exhaustive line-by-line checks, modern clinical operations utilizes a tripartite monitoring model : +---------------------------------------------+
- | TRIPARTITE MONITORING MODEL |
- +---------------------------------------------+
- |
- +---------------------------------+---------------------------------+
- | | |
- v v v
- +--------------------+ +--------------------+ +--------------------+
- | CENTRALIZED | | REMOTE | | ON-SITE |
- | MONITORING | | MONITORING | | MONITORING |
- | - Statistical CSM | | - Off-site SDR/SDV | | - In-person SDR |
- | - Cross-site KRIs | | - Electronic ISF | | - Pharmacy audit |
- | - Anomaly detection| | - Remote EMR review| | - PI debrief & fix |
- +--------------------+ +--------------------+ +--------------------+
Centralized Monitoring (Centralized Statistical Monitoring - CSM) : Remote, continuous, automated evaluation of accumulating clinical and operational data across all sites by data scientists, biostatisticians, and central clinical monitors.
Remote Monitoring (Off-Site Monitoring) : Targeted review of electronic source records (via direct, secure EMR access), electronic Investigator Site Files (eISF), and virtual regulatory documents without physical travel.
On-Site Monitoring : Focused, physical presence at the investigational site dedicated to high-value clinical reviews, physical facility and pharmacy inspections, investigative source data review, and face-to-face investigator engagement.
The Crucial Distinction: SDV vs. SDR
A cornerstone concept on the ACRP-CP examination is the profound operational and clinical distinction between Source Data Verification (SDV) and Source Data Review (SDR) . +--------------------------------------------------------------------------------------+
- | SDV: "Is the data in the EDC an exact transcription of what is in the medical chart?"|
- | SDR: "Did the site conduct the trial correctly, safely, and in compliance with GCP?" |
- +--------------------------------------------------------------------------------------+
- Comparison: SDV vs. SDR
Dimension Source Data Verification (SDV) Source Data Review (SDR)
Core Definition The mechanical process of comparing transcribed electronic Case Report Form (eCRF) data against original source records to verify that data was accurately copied. The holistic, clinical review of source documentation to evaluate protocol compliance, study conduct, clinical plausibility, patient safety, and PI oversight.
Primary Question Asked "Does the value in the EDC match the value in the source document?" "Was the study conducted properly, were safety events recognized, and was clinical judgment applied?"
Focus Areas - Transcribed lab values; - Vital signs numbers; - Dates and times of visits; - Spelling of concomitant medications; - Verification of ALCOA+ transcription - Identifying unreported Adverse Events in progress notes; - Verifying eligibility was clinically substantiated prior to dosing; - Confirming protocol-required dose adjustments were made; - Evaluating investigator oversight and delegation appropriateness
Skill / Competence Required Administrative / clerical attention to detail; pattern matching. Clinical acumen, deep protocol understanding, knowledge of medical terminology, and diagnostic interpretation.
What It Misses If Done Alone A 100% SDV check can verify that an eCRF perfectly matches a clinic note, yet completely miss that the clinic note describes severe drug-induced neuropathy that the investigator failed to record as an Adverse Event. SDR identifies safety signals, clinical protocol violations, and failures of investigator oversight that never make it into the eCRF.
Real-World Example of SDR in Action
A CRA is reviewing the medical records of Subject 104 during an on-site visit for an oncology study:
SDV View : The CRA checks the eCRF page for "Concomitant Medications" and sees "Ondansetron 8mg PO BID started on 12-Oct-2026." The CRA checks the source record, confirms the prescription matches, and marks SDV complete.
SDR View : The CRA reads the physician progress note from 12-Oct-2026: "Patient presents with severe Grade 3 nausea and persistent vomiting following Cycle 2 infusion. Prescribed ondansetron." The CRA cross-references the Adverse Event log in the eCRF and discovers that no Adverse Event of nausea/vomiting was ever logged by the site. Through SDR, the CRA identifies an unreported Grade 3 Adverse Event , issues an immediate query, and prompts the PI to submit an AE report.
Centralized Statistical Monitoring (CSM)
Centralized Monitoring uses statistical models, multivariate analysis, and automated algorithms to evaluate trial data remotely across all participating investigational sites. It operates on the principle that clinical data across large populations exhibit natural biological and statistical distributions. Accumulating Clinical Trial Data (All Sites)
- |
- v
- [Centralized Statistical Engines & KRI Dashboards]
- |
- +--------------+--------------+--------------+
- | | |
- v v v
- [Outlier Detection] [Data Quality / Fraud] [Operational Risk]
- High/Low AE rates - Digit preference - Query latency
- Unusual variance - Identical blood pres - Protocol deviations
- Missing endpoint data - Clustered dates - Screen failures
- Key Capabilities of Centralized Statistical Monitoring
Cross-Site Comparison & Outlier Detection :
Identifies sites with anomalously low or high reporting rates for adverse events, concomitant medications, or screen failures compared to national or global averages.
Flags sites where standard deviations in laboratory results or blood pressures are suspiciously narrow (suggesting synthetic data) or unusually wide (suggesting equipment calibration errors).
Detection of Data Fabrication and Fraud :
Digit Preference Analysis : Evaluates whether recorded measurements (e.g., blood pressure, weight, pain scores) exhibit an unnatural distribution of terminal digits (e.g., human fabricators disproportionately record numbers ending in '0' or '5').
Variance & Correlation Anomalies : Detects impossible correlations (e.g., identical repeated laboratory panels across different subjects or different visits).
Date and Timestamp Clustering : Flags visits recorded on weekends, national holidays, or timestamps indicating 20 complex cognitive assessments were completed in 15 minutes.
Early Safety Signal Detection :
Rapidly aggregates safety lab trends and adverse event clusters across multiple sites before individual on-site CRAs could recognize a systemic pattern.
Targeted and Tiered SDV Strategies
Under an RBQM framework, the sponsor does not eliminate SDV but transitions from indiscriminate 100% SDV to Targeted / Sampled SDV :
Data Category Target SDV Percentage Specific Data Elements Included
Tier 1: Critical Safety & Rights Data 100% SDV - Signed and dated Informed Consent Forms (all subjects); - Primary and secondary efficacy endpoint measurements; - Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs); - Inclusion/Exclusion eligibility criteria verification; - Investigational product administration and randomisation codes
Tier 2: Key Secondary Data 25% – 50% Sampled SDV - Key secondary endpoints; - Concomitant medications associated with protocol exclusions; - Non-serious AEs in a predefined random sample of subjects (e.g., first 3 subjects per site)
Tier 3: Routine / Low-Risk Data 0% – 10% (Rely on Edit Checks) - Routine non-critical lab panels (automated EDC lab range checks); - General medical history entries with no protocol relevance; - Demographic data verified at baseline
Dynamic SDV Adjustments
Targeted SDV is dynamic : if centralized monitoring or an on-site visit reveals poor data quality, high error rates, or compliance concerns at a specific site, the sponsor's monitoring plan triggers an immediate escalation of that site's SDV requirement (e.g., increasing from 25% to 100% SDV) until quality metrics return to acceptable levels.
Integration Matrix: How the Triad Operates Together
Trigger / Finding Centralized Monitoring Action Remote Monitoring Action Targeted On-Site Monitoring Action
Site has 0 AEs reported across 20 enrolled subjects KRI dashboard generates a critical red flag; biostatistician confirms statistical anomaly ( p < 0.001 p < 0.001 p < 0.001 ). CRA contacts CRC via teleconference; requests electronic source notes for initial review. CRA deploys to site for targeted Source Data Review (SDR) of clinic charts; retrains PI on AE reporting obligations.
High query turnaround time (>21 days) Automated alert issued to Clinical Project Manager. Remote monitor contacts site to review data entry bottlenecks; assists with system navigation. If unresolved, CRA audits site staffing levels and DOAL during next scheduled on-site visit.
Digit preference detected in vital signs CSM algorithm identifies terminal digit '0' in 85% of blood pressure measurements. Remote request sent for calibration logs of the automated blood pressure device. CRA physically inspects the device on-site; verifies staff measurement technique and recalibration.